Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model
MetadataShow full item record
Objectives: Chitosan is a green (natural, abundant, biodegradable, biocompatible) biopolymer that can be formulated to encapsulate a variety of therapeutic compounds. This study aimed to investigate chitosan nanoparticles (NPs) as a means of improving delivery of the clinically used anti-cancer agent doxorubicin (Dox) and the preclinical lead compound Dz13 oligonucleotide together. Methods: A novel chitosan NP system encapsulating Dox and Dz13 was designed, biophysically characterised and tested in a clinically relevant model of the metastasising bone tumour, osteosarcoma (OS). Key findings: By careful alteration of the concentration of the individual components, a final formulation of Dz13-Dox NPs (DDNPs) was achieved, with high (>91%) loading of both compounds, which consisted of individual 50-nm particles forming aggregates as large as 500 nm, with a large positive ζ-potential. The DDNPs could be stored at various temperatures for a week without loss in activity but were prone to degradation in serum. DDNPs successfully inhibited OS tumour growth more effectively than treatment with NPs of Dz13 and Dox-chitosan, as well as Dox administered intraperitoneally. Apart from inhibiting tumour growth, DDNPs protected the affected bone from substantial destruction by aggressive tumour growth and reduced the incidence of metastasis to the lungs without causing adverse effects in mice. Conclusion: This NP is a promising formulation that could be useful for clinical management of OS.
Showing items related by title, author, creator and subject.
Stimulation of bone regeneration with pigment epithelium-derived factor microparticles: Evidence in silico, in vitro and in vivoLee, P.; Martinez, Jorge; Dass, Crispin (2016)The occurrence of bone defects can be due to a variety of factors not limited to bone fractures and tumours. Most diseased bone is removed and the patient fitted with prosthetics, prior to use of certain factors such as ...
Tan, M.; Choong, P.; Dass, Crispin (2010)Used against a variety of tumours, doxorubicin (DOX), causes multiple side-effects in patients, especially in high doses required to control tumour growth. A drug delivery system (DDS) was developed to deliver DOX. Through ...
A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion siteTan, M.; Dunstan, D.; Friedhuber, A.; Choong, P.; Dass, Crispin (2010)We demonstrate that Dz13, a DNA enzyme that cleaves c-Jun mRNA, and is capable of inhibiting cancer cell growth in vitro, can be encapsulated into chitosan nanoparticles. For optimisation of this chitosan-based formulation, ...